Alkyne Derivatives of SARS-CoV-2 Main Protease Inhibitors Including Nirmatrelvir Inhibit by Reacting Covalently with the Nucleophilic Cysteine-Reference-Cited by-同舟云学术

Alkyne Derivatives of SARS-CoV-2 Main Protease Inhibitors Including Nirmatrelvir Inhibit by Reacting Covalently with the Nucleophilic Cysteine

Published:2023-02-09 Issue:4 Volume:66 Page:2663-2680
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Brewitz Lennart¹^ORCID,Dumjahn Leo¹,Zhao Yilin¹,Owen C. David²³^ORCID,Laidlaw Stephen M.⁴,Malla Tika R.¹^ORCID,Nguyen Dung⁴,Lukacik Petra²³,Salah Eidarus¹,Crawshaw Adam D.²^ORCID,Warren Anna J.²^ORCID,Trincao Jose²,Strain-Damerell Claire²³,Carroll Miles W.⁴,Walsh Martin A.²³^ORCID,Schofield Christopher J.¹^ORCID

Affiliation:

1. Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford, 12 Mansfield Road, Oxford OX1 3TA, United Kingdom

2. Diamond Light Source Ltd., Harwell Science and Innovation Campus, Didcot OX11 0DE, United Kingdom

3. Research Complex at Harwell, Harwell Science and Innovation Campus, Didcot OX11 0FA, United Kingdom

4. Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7BN, United Kingdom

Funder

Oak Foundation

University of Oxford

King Abdulaziz University

Wellcome Trust

Biotechnology and Biological Sciences Research Council

Cancer Research UK

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.2c01627

Reference109 articles.

1. An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19

2. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

3. Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities

4. Viral Proteases as Targets for Coronavirus Disease 2019 Drug Development

5. A review of the latest research on Mpro targeting SARS-COV inhibitors

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Peptidyl nitroalkene inhibitors of main protease rationalized by computational and crystallographic investigations as antivirals against SARS-CoV-2;Communications Chemistry;2024-01-18

2. On the origins of SARS-CoV-2 main protease inhibitors;RSC Medicinal Chemistry;2024

3. コバレントドラッグのための細胞内反応化学;Journal of Synthetic Organic Chemistry, Japan;2024-01-01

4. Discovery of Orally Available and Brain Penetrant AEP Inhibitors;Journal of Medicinal Chemistry;2023-12-13

5. Identification of key residues in MERS-CoV and SARS-CoV-2 main proteases for resistance against clinically applied inhibitors nirmatrelvir and ensitrelvir;2023-12-04